Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 13Recruiting 5Unknown 4Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Low Risk Differentiated Thyroid Cancer 1

Interventions

pembrolizumab 66Cisplatin 55Radiotherapy, Intensity-Modulated 28Carboplatin 27Nivolumab 26Paclitaxel 21Magnetic Resonance Spectroscopy 21Radiotherapy 20Cetuximab 16Specimen Handling 15Docetaxel 15Radiation 14Gemcitabine 13Fluorouracil 12Biopsy 12durvalumab 11Platinum 11Taxes 10Drug Therapy 101,2-diaminocyclohexaneplatinum II citrate 10Surveys and Questionnaires 9Capecitabine 9trametinib 8tislelizumab 6lenvatinib 6dabrafenib 6cemiplimab 6atezolizumab 6Radiosurgery 6Ipilimumab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Thyrotropin Alfa × Head & Neck × Clear all
NCT01837745 2023-05-17

ESTIMABL2

Gustave Roussy, Cancer Campus, Grand Paris

Phase 3 Active not recruiting
776 enrolled
EndocrineHead & Neck

Low Risk Differentiated Thyroid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡